Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
The new Q-View Imager Plus, along with the updated Q-View Software, provide consistent, high-quality data, for use in academic, biopharma, and clinical laboratories.
Share
At the core of the Q-View™ Imager Plus is a 35-megapixel multi-camera system with temperature-controlled sensors, offering high resolution images and consistent data quality across every plate. This design ensures reliable performance for both research and regulated laboratory environments, making it one of the most advanced imaging solutions in its class.
'We designed the Q-View™ Imager Plus and its upgraded Q-View™ Software to provide labs with consistent, high-quality data,' said Adam Brown, CEO at Quansys Biosciences. 'By combining advanced imaging with power and intuitive analysis tools, we have been able to deliver on our commitment to empower labs with tools that simplify complex workflows and deliver high-impact results, faster.'
While most plate readers merely scan data points, the Q-View™ Imager Plus captures crystal-clear photographic images of 96-well plates and processes them in real time, allowing scientists to extract more meaningful results with less variability. The improved system extracts richer data with confidence, with active cooling ensuring consistent data from one image to the next, which is an essential requirement for clinical and regulatory settings.
Key features include:
Pre-focused optics for plug-and-play performance
Integrated barcode scanning for automatic plate identification and reduced user error
Internal qualification lighting for precise calibration without the need for external powered devices
Durable and compact design, ideal for crowded lab environments
Energy-saving mode to minimize wear, energy use, and noise when idle
Compatible with automation and liquid handlers for high-throughput labs
Field-upgradable firmware ensures longevity and adaptability
'Our goal with the Q-View Imager Plus was to give scientists a tool that combines high-quality imaging with practical usability,' said Dr. Kyle Berg PhD, who leads the R&D team at Quansys Biosciences. 'Every feature, from the pre-focuses optics to the integrated software, was engineered to reduce variability and make multiplex ELISA workflows faster and more reliable.'
Availability
The Q-View™ Imager Plus is now available for purchase worldwide. To request pricing or more information, visit www.quansysbio.com/q-view-imager-plus, or contact sales@quansysbio.com.
About Quansys Biosciences
Quansys Biosciences is a leading biotechnology company specializing in multiplex ELISA testing solutions and quantitative protein analysis for both research and clinical applications. Its Q-Plex™ product line, Q-View™ Software, and Q-View™ Imagers are trusted by scientists and clinicians around the world to study a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. By delivering tools that improve efficiency, accuracy, and insight, Quansys empowers laboratories to generate high-quality biomarker data with confidence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
A $10 Billion Reason to Buy Palantir Stock
Palantir Technologies (PLTR) is a leading software company that focuses on helping organizations make sense of large and complex data. Its platforms use advanced analytics and artificial intelligence to integrate various types of data, enabling customers, including government agencies and businesses in industries such as finance, healthcare, and energy, to gain simplified insights that facilitate better decision-making. Founded in 2003, the company is headquartered in Denver, Colorado. More News from Barchart Elon Musk Predicts Tesla Will 'Have Autonomous Ride-Hailing in Probably Half the Population of the US by the End of the Year' Should You Buy the 40% Post-Earnings Plunge in The Trade Desk Stock? Wedbush Thinks Palantir Is Speeding to $1 Trillion. Should You Buy PLTR Stock Now? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! About Palantir Stock Palantir's stock has been one of the standout performers in 2025, gaining more than 147% YTD, easily outpacing the benchmark S&P 500 Index's ($SPX) more modest 8.7% jump. The stock trades at its 52-week and all-time highs, having achieved nearly 550% growth over the past year. Moreover, it continues its rally with a 21.5% gain in five days and a 34% gain in a month. Palantir Posts Q2 Results Palantir posted its second-quarter results on Monday, Aug. 4. It reported adjusted earnings of $0.16 per share, beating analysts' $0.14 per share estimate, a significant 77% rise from the same quarter last year. The company also posted a record revenue figure, which stood at $1 billion, marking a 48% rise while surpassing estimates of $939 million. Palantir's U.S. commercial revenue jumped 93% to $306 million while U.S. government revenue rose 53% to $426 million. Beyond headline numbers, Palantir strengthened its financial position with record contract momentum: 157 contracts worth at least $1 million, 66 contracts worth at least $5 million, and 42 contracts of $10 million or more in Q2. Adjusted operating income hit $464 million, boosted by margin expansion to 46%, continuing an upward trend quarter-over-quarter. It had a free cash flow of $569 million with a 57% margin while cash reserves stood at $6 billion with zero debt. Looking ahead, Palantir raised its full-year 2025 revenue guidance to $4.142 billion to $4.15 billion, up from the previous forecast of $3.89 billion to $3.9 billion. The company also expects ongoing contract wins and growth in both government and commercial sectors, fueled by accelerating adoption of its Artificial Intelligence Platform and a recent multibillion-dollar U.S. Army contract. Palantir Wins U.S. Army Deal Palantir Technologies has secured a landmark contract with the U.S. Army valued at up to $10 billion over the next decade, marking the largest Department of Defense deal ever awarded to the company. The contract is a new enterprise agreement, which consolidates 75 existing contracts, including 15 prime contracts and 60 related ones, into a single streamlined contract intended to enhance military readiness and boost operational efficiency. The consolidation reduces procurement timelines, allowing soldiers quicker access to Palantir's advanced data integration, analytics, and AI tools. The deal also establishes volume-based discounts and provides the Army and other Department of Defense (DoD) entities flexibility to purchase Palantir's commercial products as needed, though total spending will not exceed the $10 billion cap. This contract significantly strengthens Palantir's role as a key technology provider for the military, while also driving cost savings and procurement simplification for the Army. Should You Buy Palantir? The stock has a consensus 'Hold' rating with a mean price target of $147.50 which is well below its trading price, but it is worth noting that Palantir trades at an all-time high with strong momentum that has analysts playing catch up with its performance. It has been rated by 21 analysts with four 'Strong Buy' ratings, 14 'Hold' ratings, one 'Moderate Sell' rating, and two 'Strong Sell' ratings. On the date of publication, Ruchi Gupta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Wire
12 hours ago
- Business Wire
TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at July 31, 2025
PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) Total number of exercisable voting rights, after deduction of 87,252,159 treasury shares.
Yahoo
14 hours ago
- Yahoo
Why Health Catalyst (HCAT) Stock Is Down Today
What Happened? Shares of healthcare software provider Health Catalyst (NASDAQ:HCAT) fell 21.5% in the afternoon session after the company reported second-quarter results that met expectations but slashed its full-year revenue forecast and provided a weak outlook for the upcoming quarter. The healthcare software provider's revenue of $80.72 million and adjusted earnings per share of $0.04 were both in line with Wall Street estimates for the second quarter. However, investors were focused on the future, as the company projected third-quarter revenue of $75 million, which was roughly 12% below analyst expectations. Furthermore, Health Catalyst cut its full-year revenue forecast by 7.5% to $310 million. While the company did beat adjusted EBITDA estimates for the quarter and raised its full-year outlook for the metric, the significant reduction in its revenue guidance overshadowed the positive news, sending shares lower. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it's free. What Is The Market Telling Us Health Catalyst's shares are extremely volatile and have had 41 moves greater than 5% over the last year. But moves this big are rare even for Health Catalyst and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 3.1% on the news that the Software as a Service (SaaS) sector rebounded following the sell-off in the previous trading session as a weaker-than-expected U.S. jobs report increased the probability of a Federal Reserve interest rate cut. The July Nonfarm Payrolls (NFP) report showed the U.S. economy added only 73,000 jobs, significantly below the 110,000 forecast. This, combined with downward revisions for May and June, signaled a cooling labor market to investors. In response, market expectations for a September interest rate cut by the Federal Reserve surged from roughly 40% to over 80%. A potential rate cut is generally favorable for growth sectors like technology and SaaS, as lower rates can increase the present value of their future earnings, boosting stock valuations. Health Catalyst is down 61.1% since the beginning of the year, and at $2.86 per share, it is trading 68.3% below its 52-week high of $9.02 from December 2024. Investors who bought $1,000 worth of Health Catalyst's shares 5 years ago would now be looking at an investment worth $81.22. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
